CN107530323B - 依替福辛的氘化类似物、其衍生物及它们的用途 - Google Patents

依替福辛的氘化类似物、其衍生物及它们的用途 Download PDF

Info

Publication number
CN107530323B
CN107530323B CN201680028306.5A CN201680028306A CN107530323B CN 107530323 B CN107530323 B CN 107530323B CN 201680028306 A CN201680028306 A CN 201680028306A CN 107530323 B CN107530323 B CN 107530323B
Authority
CN
China
Prior art keywords
disorder
disorders
compound
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680028306.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107530323A (zh
Inventor
奥利维尔·达斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gaba Therapeutics Co ltd
Original Assignee
Gaba Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gaba Therapeutics Co Ltd filed Critical Gaba Therapeutics Co Ltd
Publication of CN107530323A publication Critical patent/CN107530323A/zh
Application granted granted Critical
Publication of CN107530323B publication Critical patent/CN107530323B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201680028306.5A 2015-03-20 2016-03-18 依替福辛的氘化类似物、其衍生物及它们的用途 Active CN107530323B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562135979P 2015-03-20 2015-03-20
US62/135,979 2015-03-20
PCT/US2016/023231 WO2016154039A1 (en) 2015-03-20 2016-03-18 Deuterated analogs of etifoxine, their derivatives and uses therof

Publications (2)

Publication Number Publication Date
CN107530323A CN107530323A (zh) 2018-01-02
CN107530323B true CN107530323B (zh) 2021-05-04

Family

ID=56977741

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680028306.5A Active CN107530323B (zh) 2015-03-20 2016-03-18 依替福辛的氘化类似物、其衍生物及它们的用途

Country Status (21)

Country Link
US (4) US10080755B2 (enExample)
EP (1) EP3347006B1 (enExample)
JP (3) JP6762507B2 (enExample)
KR (1) KR102290766B1 (enExample)
CN (1) CN107530323B (enExample)
AU (2) AU2016235495B2 (enExample)
BR (1) BR112017020081B1 (enExample)
CA (1) CA2979853C (enExample)
DK (1) DK3347006T3 (enExample)
ES (1) ES2928396T3 (enExample)
HR (1) HRP20221240T1 (enExample)
HU (1) HUE060240T2 (enExample)
IL (2) IL270627B2 (enExample)
LT (1) LT3347006T (enExample)
MX (1) MX383647B (enExample)
PL (1) PL3347006T3 (enExample)
PT (1) PT3347006T (enExample)
RS (1) RS63654B1 (enExample)
SI (1) SI3347006T1 (enExample)
SM (1) SMT202200407T1 (enExample)
WO (1) WO2016154039A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016154039A1 (en) * 2015-03-20 2016-09-29 Anvyl, Llc Deuterated analogs of etifoxine, their derivatives and uses therof
US10420773B2 (en) 2017-09-26 2019-09-24 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with etifoxine
WO2019183564A1 (en) * 2018-03-23 2019-09-26 Concert Pharmaceuticals, Inc. DEUTERATED ANALOGS OF D-β-HYDROXYBUTYRIC ACID AND USES THEREOF
MX2020012407A (es) * 2018-05-18 2021-02-09 Ovid Therapeutics Inc Metodos de tratamiento del trastorno de deficit de atencion e hiperactividad.
CN112125862A (zh) * 2019-06-25 2020-12-25 上海安谱实验科技股份有限公司 一种稳定同位素标记的阿特拉津-d5及其合成方法
US11534434B2 (en) 2019-11-15 2022-12-27 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
WO2023040851A1 (zh) * 2021-09-14 2023-03-23 南京迈诺威医药科技有限公司 一种水溶性别孕烷醇酮衍生物及其制备方法和用途
WO2023218251A1 (en) * 2022-05-10 2023-11-16 Clearsynth Labs Limied Novel deuterium-enriched nefazodone analogues and method for preparing thereof
US20240189316A1 (en) * 2022-10-24 2024-06-13 Gaba Therapeutics Inc. Deuterated analogs of etifoxine and methods of administration without autoinduction of metabolism
WO2025085958A1 (en) * 2023-10-23 2025-05-01 Glomesh Intl Pty Ltd A module for mounting items

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670772C3 (de) 1966-11-24 1978-04-20 Hoechst Ag, 6000 Frankfurt 4H-3,1-Benzoxazin-Derivate, deren Salze und pharmazeutische Präparate
FR2888748B1 (fr) 2005-07-19 2007-10-12 Biocodex Composes neuroprotecteurs et compositions pharmaceutiques les comprenant
US8110569B2 (en) * 2006-03-20 2012-02-07 The Regents Of The University Of California Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use
WO2007109288A2 (en) * 2006-03-20 2007-09-27 Xytis Inc. Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use
JP2011001308A (ja) * 2009-06-19 2011-01-06 Research Foundation Itsuu Laboratory 重水素化カルボスチリル化合物
MX2013000333A (es) * 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
EP2730559A4 (en) 2011-07-05 2015-03-04 Kemphys Ltd DEUTERATED PHENYLPROPIONIC ACID DERIVATIVE
FR3016881B1 (fr) 2014-01-29 2016-03-04 Biocodex Traitement des degenerescences et des lesions photo-induites de la retine
WO2016154039A1 (en) * 2015-03-20 2016-09-29 Anvyl, Llc Deuterated analogs of etifoxine, their derivatives and uses therof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
1246815-89-3;REGISTRY;《STN》;20101022 *
1346598-10-4;REGISTRY;《STN》;20111130 *
Derivatives of tramadol for increased duration of effect;Liming Shao等;《Bioorganic & Medicinal Chemistry Letters》;20051027;第16卷;691-694 *
Determination of the mechanism of demethylenation of (methylenedioxy)phenyl compounds by cytochrome P450 using deuterium isotope effects;Jon M. Fukuto等;《J. Med. Chem.》;19911231;第34卷(第9期);2871-2876 *
Etifoxine for Pain Patients with Anxiety;Yun Mi Choi和Kyung Hoon Kim;《Korean J Pain》;20150131;第28卷(第1期);4-10 *

Also Published As

Publication number Publication date
SI3347006T1 (sl) 2022-11-30
IL254567B (en) 2020-03-31
US20180064717A1 (en) 2018-03-08
IL254567A0 (en) 2017-11-30
IL270627B (en) 2022-11-01
JP2018508592A (ja) 2018-03-29
IL270627B2 (en) 2023-03-01
EP3347006A4 (en) 2019-04-24
EP3347006B1 (en) 2022-07-27
HUE060240T2 (hu) 2023-02-28
DK3347006T3 (da) 2022-10-17
US10080755B2 (en) 2018-09-25
IL270627A (enExample) 2019-12-31
PT3347006T (pt) 2022-10-17
BR112017020081A2 (pt) 2018-06-05
EP3347006A1 (en) 2018-07-18
US20190015419A1 (en) 2019-01-17
JP6762507B2 (ja) 2020-09-30
US20230263805A1 (en) 2023-08-24
ES2928396T3 (es) 2022-11-17
KR102290766B1 (ko) 2021-08-19
JP2023009114A (ja) 2023-01-19
JP2021001174A (ja) 2021-01-07
PL3347006T3 (pl) 2022-11-14
BR112017020081B1 (pt) 2021-11-30
AU2020201728B2 (en) 2021-12-23
US20200405726A1 (en) 2020-12-31
MX2017011978A (es) 2018-02-09
US11672805B2 (en) 2023-06-13
LT3347006T (lt) 2022-10-25
RS63654B1 (sr) 2022-11-30
WO2016154039A1 (en) 2016-09-29
CN107530323A (zh) 2018-01-02
CA2979853A1 (en) 2016-09-29
US10736901B2 (en) 2020-08-11
AU2016235495A1 (en) 2017-10-05
AU2020201728A1 (en) 2020-03-26
CA2979853C (en) 2021-05-11
AU2016235495B2 (en) 2020-05-14
KR20170137085A (ko) 2017-12-12
MX383647B (es) 2025-03-14
HRP20221240T1 (hr) 2022-12-09
US12433896B2 (en) 2025-10-07
SMT202200407T1 (it) 2022-11-18
JP7376668B2 (ja) 2023-11-08

Similar Documents

Publication Publication Date Title
CN107530323B (zh) 依替福辛的氘化类似物、其衍生物及它们的用途
US6337328B1 (en) Bupropion metabolites and methods of use
WO2007109288A2 (en) Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use
CN101022806A (zh) （4－烷基哌嗪基）（苯基）甲酮在治疗阿尔茨海默病中的应用
EP2007741A1 (en) Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use
CN102317261A (zh) 三重再摄取抑制剂及其应用方法
Nilsson et al. Amide, urea, and carbamate analogs of the muscarinic agent [4-[[N-(3-chlorophenyl) carbamoyl] oxy]-2-butynyl] trimethylammonium chloride
US20240189316A1 (en) Deuterated analogs of etifoxine and methods of administration without autoinduction of metabolism
JP7073272B2 (ja) 神経伝達物質放出剤としてのビニローグフェネチルアミン
AU2005247034A1 (en) Bupropion metabolites and methods of their synthesis and use
HK1144937A (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200909

Address after: California, USA

Applicant after: GABA therapeutics Co.,Ltd.

Address before: California, USA

Applicant before: GABA therapeutics Co.,Ltd.

Effective date of registration: 20200909

Address after: California, USA

Applicant after: GABA therapeutics Co.,Ltd.

Address before: California, USA

Applicant before: Anvyl LLC

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant